Overview

First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NOX-H94

Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
This is the first clinical trial with NOX-H94. The purpose of this clinical trial is to identify a safe and efficacious treatment regimen for the clinical development of NOX-H94 in patients with anemia of chronic disease (inflammation).
Phase:
Phase 1
Details
Lead Sponsor:
NOXXON Pharma AG